stockrowGSK PLC Sponsored ADR
GSK Healthcare Drug Manufacturers General
GSK PLC Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $43.1 billion, up 7.44% from fiscal 2024.
- Revenue
- +3.75%
- EPS
- −14.7%
- Free cash flow
- +62.4%
- Total debt
- +33.2%
Quarter to September 2026, against a year earlier
Follow GSK
Alert me
GSK PLC Sponsored ADR (GSK) Return on assets
GSK PLC Sponsored ADR's return on assets over the twelve months to 30 September 2026 was 6.53%, down 3.1 percentage points from fiscal 2025 (9.63%). Over the past ten years it has ranged from 1.53% (fiscal 2016) to 20.2% (fiscal 2022); the current reading is higher than 82% of that period. That is above the Drug Manufacturers General industry median of 2.28% and above the Healthcare sector median of −29.3%.
Return on assets, annual
Embed this chart
Annual newest first
| Period | Return on assets | Change (points) |
|---|---|---|
| FY2025 | 9.63% | 5.22 |
| FY2024 | 4.41% | (3.89) |
| FY2023 | 8.30% | (11.90) |
| FY2022 | 20.2% | 14.51 |
| FY2021 | 5.69% | (1.51) |
| FY2020 | 7.20% | 0.58 |
| FY2019 | 6.62% | 0.18 |
| FY2018 | 6.44% | 3.85 |
| FY2017 | 2.59% | 1.06 |
| FY2016 | 1.53% | (15.79) |
Against its own ten years
Return on assets against peers
| Company | Return on assets |
|---|---|
| NVO Novo Nordisk A/S compare | 22.0% |
| AMGN Amgen Inc. compare | 10.1% |
| BMY Bristol Myers Squibb Company compare | 9.96% |
| AZN AstraZeneca PLC compare | 9.41% |
| GSK GSK PLC Sponsored ADR | 6.53% |
| SNY Sanofi compare | 3.24% |
| PFE Pfizer Inc. compare | 1.95% |
| BIIB Biogen Inc. compare | 1.13% |
| GILD Gilead Sciences, Inc. compare | −7.03% |
| Drug Manufacturers General industry median | 2.28% |
| Healthcare sector median | −29.3% |
| Market median | 0.00% |
What Return on assets is
ROA tells an investor how much profit a company earns for shareholders from the assets it uses to run its business.
Annual: Net Income Allotted to Shareholders ÷ Average Assets; TTM: Net Income Allotted to Shareholders ÷ Average Assets (latest quarter)
More on GSK
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement